SUMMARY

BEPREVE®:1

downarrow icon

Demonstrated a significant reduction in ocular itch at 3 minutes post CAC at the onset of action, 8-hour and 16-hour visits

check mark icon

Primary mechanisms of action include:1†

  • Non-sedating, selective antagonism of H1-histamine receptors
  • Mast-cell stabilization
  • Inhibitory action on eosinophilic migration to inflammatory sites
  • Suppression of vascular permeability
check mark icon

Product characteristics†

  • Low Benzalkonium Chloride (BAK) concentration of 0.005%
  • pH of 6.8
  • Comes in low-density polyethylene plastic squeeze bottle
  • Available in 5 mL bottle1
product box

† Clinical significance has not been established

References:

  1. BEPREVE® Product Monograph. Bausch & Lomb Incorporated. July 22, 2016.
  2. Abelson MB et al. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: A phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children. Clin Ther 2009;31:1908–21.
  3. Data on file, Bausch & Lomb Incorporated, 2017.